DAGLA: A Potential Drug Target for Neurological Disorders (G747)

Target Name: DAGLA

NCBI ID: G747

DAGLA

DAGLA: A Potential Drug Target for Neurological Disorders

DAGLA (Deoxyinosaccharide-Actinyl-L-Aspartate) is a molecule that has been identified as a potential drug target (DMR) and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in these conditions.

DAGLA is a truncated protein that is composed of 21 amino acids. It is found in various tissues throughout the body, including the brain, where it is involved in the formation and maintenance of synapses, the structures that allow nerve cells to communicate with each other.

One of the key features of DAGLA is its ability to interact with a protein called TrkB, which is a known modifier of the neurotransmitter dopamine. TrkB is a transmembrane protein that is involved in the transportation of dopamine across the blood-brain barrier, which is a barrier that separates the brain from the blood.

Research has shown that DAGLA and TrkB can interact with each other and that this interaction may play a role in the regulation of dopamine levels in the brain. This suggests that DAGLA may be a useful biomarker or drug target for disorders related to dopamine dysfunction, such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which DAGLA may be involved in the development of these disorders is its role in the regulation of the microglial cells, which are a type of immune cell that are found in the brain. Microglial cells are involved in the immune response and are thought to play a role in the development of neurodegenerative disorders.

Research has shown that DAGLA can interact with microglial cells and that this interaction may be involved in the regulation of microglial cell function. This suggests that DAGLA may be a useful drug target or biomarker for disorders related to neurodegenerative diseases.

In addition to its potential role in the regulation of dopamine and microglial cells, DAGLA has also been shown to play a role in the regulation of cell survival. Studies have shown that DAGLA can interact with the protein Bcl-2, which is a protein that is involved in the regulation of cell survival.

This interaction between DAGLA and Bcl-2 suggests that DAGLA may be a useful target for drugs that are aimed at preventing or treating neurodegenerative disorders.

Overall, DAGLA is a molecule that has the potential to be a drug target or biomarker for a variety of neurological and psychiatric disorders. Its unique structure and biology, as well as its ability to interact with TrkB and microglial cells, make it an attractive target for researchers to study. Further research is needed to fully understand the role of DAGLA in these disorders and to develop effective treatments.

Protein Name: Diacylglycerol Lipase Alpha

Functions: Serine hydrolase that hydrolyzes arachidonic acid-esterified diacylglycerols (DAGs) to produce the principal endocannabinoid, 2-arachidonoylglycerol (2-AG) (PubMed:14610053, PubMed:26668358, PubMed:23502535). Preferentially hydrolyzes sn-1 fatty acids from diacylglycerols (DAG) that contain arachidonic acid (AA) esterified at the sn-2 position to biosynthesize 2-AG (PubMed:14610053, PubMed:26668358, PubMed:23502535). Has negligible activity against other lipids including monoacylglycerols and phospholipids (PubMed:14610053). Plays a key role in regulating 2-AG signaling in the central nervous system (CNS). Regulates 2-AG involved in retrograde suppression at central synapses. Supports axonal growth during development and adult neurogenesis. Plays a role for eCB signaling in the physiological regulation of anxiety and depressive behaviors. Regulates also neuroinflammatory responses in the brain, in particular, LPS-induced microglial activation (By similarity)

The "DAGLA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAGLA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets